Latest News

FDA Accepts Galderma’s BLA for Nemolizumab for the Treatment of Prurigo Nodularis and Atopic Dermatitis
FDA Accepts Galderma’s BLA for Nemolizumab for the Treatment of Prurigo Nodularis and Atopic Dermatitis

February 14th 2024

The FDA has also granted nemolizumab Priority Review for prurigo nodularis.

Dermavant Submits sNDA to FDA for Tapinarof Cream 1% to Treat AD Down to 2 Years
Dermavant Submits sNDA to FDA for Tapinarof Cream 1% to Treat AD Down to 2 Years

February 14th 2024

IGA, EASI, and Itch Endpoints Met in First In Human Phase 2 Trial of Zabalafin for Atopic Dermatitis
IGA, EASI, and Itch Endpoints Met in First In Human Phase 2 Trial of Zabalafin for Atopic Dermatitis

February 9th 2024

Communication Is Key in Atopic Dermatitis Treatment
Communication Is Key in Atopic Dermatitis Treatment

February 9th 2024

Clothianidin Exposure Suppresses Early Symptoms of AD in Mouse Model Study
Clothianidin Exposure Suppresses Early Symptoms of AD in Mouse Model Study

February 7th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.